Who founded Deciduous Therapeutics?

Deciduous Therapeutics was founded by Robin Mansukhani, Anil Bhushan in 2018.

Who are Deciduous Therapeutics's investors?

Deciduous Therapeutics's investors include age1, Bold Capital Partners, Cornucopian Capital Management, CRV (Charles River Ventures), Gaingels, Lifespan Vision Ventures, Mana Ventures, Owl Capital and 2 more.

How much funding has Deciduous Therapeutics raised?

Deciduous Therapeutics has disclosed $5.8M raised across 1 round.

Where is Deciduous Therapeutics headquartered?

Deciduous Therapeutics is headquartered in San Francisco, US.

Deciduous Therapeutics

San Francisco, US · Founded 2018 · Delaware corporation · 10 known investors

Find your way into Deciduous Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Deciduous Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders. The company serves patients with conditions driven by cellular aging and senescence.

Biotech Digital Health Longevity

Founders & leadership

Deciduous Therapeutics was founded in 2018 by Robin Mansukhani and Anil Bhushan.

Robin Mansukhani CEO and Co-FounderRobin Mansukhani is CEO and co-founder of Deciduous Therapeutics, which develops immunomodulatory therapies targeting senescent cells for age-related diseases. He previously co-founded and led Alzeca Biosciences, a CNS diagnostic imaging company, and has worked in early-stage venture capital and investment banking; he holds a B.S. in Biochemistry from Case Western Reserve University.

Anil Bhushan Scientific FounderAnil Bhushan is a Professor of Medicine at UCSF with training from the Salk Institute and Institut Curie, and an independent laboratory background at UCLA. He studies stromal immunology and tissue microenvironments, with research focused on beta cell biology and the role of chromatin regulation in endocrine function, and co-founded Deciduous Therapeutics in 2019 to develop immunological therapies targeting senescent cells.

Board

Dylan Morris Board DirectorManaging Director at Insight Partners

Investors · 10

age1listed by age1San Francisco · $500K – $4M

How we know: age1's portfolio page · Not right? Tell us

Bold Capital Partnerslisted by Bold Capital PartnersSanta Monica

How we know: Bold Capital Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Cornucopian Capital Managementlisted by Cornucopian Capital ManagementMontclair

CRV (Charles River Ventures)listed by CRV (Charles River Ventures)Bay Area · $250K – $5M

How we know: CRV (Charles River Ventures)'s portfolio page · Not right? Tell us

Gaingelslisted by GaingelsNew York · $200K – $500K

How we know: gaingels.com · Not right? Tell us

Lifespan Vision Ventureslisted by Lifespan Vision VenturesNorwalk

How we know: Lifespan Vision Ventures's portfolio page · Not right? Tell us

Mana Ventureslisted by Mana VenturesEstero

How we know: the VCSheet dataset · Not right? Tell us

Owl Capitallisted by Owl Capitalvia Jennifer Fonstad · inferred

quadraScope Venture Fundlisted by quadraScope Venture FundBoston

How we know: quadraScope Venture Fund's portfolio page · Not right? Tell us

Axial VCreportedSan Francisco · $100K – $5M

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$5.8M disclosed across 1 round · 2019

▶$5.8MraisedJul 2019 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Robin MansukhaniExecutive Officer, Director
Dylan MorrisDirector
Anil BhushanDirector

Offering amount: $6.5M
Amount sold: $5.8M
Minimum investment: $10K
First sale: Jun 2019
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 7

Dialectic TherapeuticsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.

Dewpoint TherapeuticsDewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms. Its discovery engine combines biology, chemistry, proprietary datasets, and AI to pursue therapies for complex diseases, including previously undruggable targets.

Edgewise TherapeuticsEdgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.

Celldex Therapeutics, Inc.Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.

Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.

PreqinPreqin provides a data and intelligence platform for investment teams, M&A professionals, and corporate development teams to source, evaluate, and value private company investments through integrated asset, fund, and performance data.

Companies working in the same space as Deciduous Therapeutics.

Frequently asked questions

What does Deciduous Therapeutics do?: Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders. The company serves patients with conditions driven by cellular aging and senescence.
Who founded Deciduous Therapeutics?: Deciduous Therapeutics was founded by Robin Mansukhani, Anil Bhushan in 2018.
Who are Deciduous Therapeutics's investors?: Deciduous Therapeutics's investors include age1, Bold Capital Partners, Cornucopian Capital Management, CRV (Charles River Ventures), Gaingels, Lifespan Vision Ventures, Mana Ventures, Owl Capital and 2 more.
How much funding has Deciduous Therapeutics raised?: Deciduous Therapeutics has disclosed $5.8M raised across 1 round.
Where is Deciduous Therapeutics headquartered?: Deciduous Therapeutics is headquartered in San Francisco, US.